Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Charles N Catton

Showing results (81-90 of 89) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 89 results.
Urology|August 2, 2008
A multi-institutional matched-control analysis of adjuvant and salvage postoperative radiation therapy for pT3-4N0 prostate cancerEdouard J Trabulsi, Richard K Valicenti, Alexandra L Hanlon, et al.
The Journal of Urology|August 29, 2018
International Multicenter Validation of an Intermediate Risk Subclassification of Prostate Cancer Managed with Radical Treatment without Hormone TherapyAlejandro Berlin, Fabio Y Moraes, Noelia Sanmamed, et al.
European Urology|June 26, 2025
Duration of Androgen Suppression with Postoperative Radiotherapy (DADSPORT) for Nonmetastatic Prostate Cancer: A Collaborative Systematic Review and Meta-analysis of Aggregate DataSarah Burdett, David J Fisher, Jayne F Tierney, et al.
The Lancet. Oncology|February 2, 2025
The interplay between acute and late toxicity among patients receiving prostate radiotherapy: an individual patient data meta-analysis of six randomised trialsJohn Nikitas, Parsa Jamshidian, Alison C Tree, et al.
International Journal of Radiation Oncology, Biology, Physics|February 9, 2026
Correlation of Biochemical Recurrence with Adverse Late Toxic Events Following Prostate Radiotherapy (COBALT Study): An Individual Patient Data Meta-Analysis of 7 Randomized TrialsJohn Nikitas, Parsa Jamshidian, Alison C Tree, et al.
The Lancet. Oncology|March 20, 2025
Hypofractionated radiotherapy for prostate cancer (HYDRA): an individual patient data meta-analysis of randomised trials in the MARCAP consortiumAmar U Kishan, Yilun Sun, Alison C Tree, et al.
Lancet (London, England)|May 19, 2024
Duration of androgen deprivation therapy with postoperative radiotherapy for prostate cancer: a comparison of long-course versus short-course androgen deprivation therapy in the RADICALS-HD randomised trialChris C Parker, Howard Kynaston, Adrian D Cook, et al.
Lancet (London, England)|May 19, 2024
Adding 6 months of androgen deprivation therapy to postoperative radiotherapy for prostate cancer: a comparison of short-course versus no androgen deprivation therapy in the RADICALS-HD randomised controlled trialChris C Parker, Noel W Clarke, Adrian D Cook, et al.
Annals of Surgical Oncology|June 29, 2022
Management of Locally Recurrent Retroperitoneal Sarcoma in the Adult: An Updated Consensus Approach from the Transatlantic Australasian Retroperitoneal Sarcoma Working GroupWilliam W Tseng, Carol J Swallow, Dirk C Strauss, et al.
Pageof 9

Showing results (81-90 of 89) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 89 results.
Urology|August 2, 2008
A multi-institutional matched-control analysis of adjuvant and salvage postoperative radiation therapy for pT3-4N0 prostate cancerEdouard J Trabulsi, Richard K Valicenti, Alexandra L Hanlon, et al.
The Journal of Urology|August 29, 2018
International Multicenter Validation of an Intermediate Risk Subclassification of Prostate Cancer Managed with Radical Treatment without Hormone TherapyAlejandro Berlin, Fabio Y Moraes, Noelia Sanmamed, et al.
European Urology|June 26, 2025
Duration of Androgen Suppression with Postoperative Radiotherapy (DADSPORT) for Nonmetastatic Prostate Cancer: A Collaborative Systematic Review and Meta-analysis of Aggregate DataSarah Burdett, David J Fisher, Jayne F Tierney, et al.
The Lancet. Oncology|February 2, 2025
The interplay between acute and late toxicity among patients receiving prostate radiotherapy: an individual patient data meta-analysis of six randomised trialsJohn Nikitas, Parsa Jamshidian, Alison C Tree, et al.
International Journal of Radiation Oncology, Biology, Physics|February 9, 2026
Correlation of Biochemical Recurrence with Adverse Late Toxic Events Following Prostate Radiotherapy (COBALT Study): An Individual Patient Data Meta-Analysis of 7 Randomized TrialsJohn Nikitas, Parsa Jamshidian, Alison C Tree, et al.
The Lancet. Oncology|March 20, 2025
Hypofractionated radiotherapy for prostate cancer (HYDRA): an individual patient data meta-analysis of randomised trials in the MARCAP consortiumAmar U Kishan, Yilun Sun, Alison C Tree, et al.
Lancet (London, England)|May 19, 2024
Duration of androgen deprivation therapy with postoperative radiotherapy for prostate cancer: a comparison of long-course versus short-course androgen deprivation therapy in the RADICALS-HD randomised trialChris C Parker, Howard Kynaston, Adrian D Cook, et al.
Lancet (London, England)|May 19, 2024
Adding 6 months of androgen deprivation therapy to postoperative radiotherapy for prostate cancer: a comparison of short-course versus no androgen deprivation therapy in the RADICALS-HD randomised controlled trialChris C Parker, Noel W Clarke, Adrian D Cook, et al.
Annals of Surgical Oncology|June 29, 2022
Management of Locally Recurrent Retroperitoneal Sarcoma in the Adult: An Updated Consensus Approach from the Transatlantic Australasian Retroperitoneal Sarcoma Working GroupWilliam W Tseng, Carol J Swallow, Dirk C Strauss, et al.
Pageof 9